SG11202105743RA - Methods for treating or preventing gout or hyperuricemia - Google Patents
Methods for treating or preventing gout or hyperuricemiaInfo
- Publication number
- SG11202105743RA SG11202105743RA SG11202105743RA SG11202105743RA SG11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperuricemia
- treating
- methods
- preventing gout
- gout
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776251P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/064785 WO2020118114A1 (en) | 2018-12-06 | 2019-12-05 | Methods for treating or preventing gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105743RA true SG11202105743RA (en) | 2021-06-29 |
Family
ID=70974386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105743RA SG11202105743RA (en) | 2018-12-06 | 2019-12-05 | Methods for treating or preventing gout or hyperuricemia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220023251A1 (en) |
| EP (1) | EP3890722A4 (en) |
| JP (1) | JP2022510303A (en) |
| KR (1) | KR20210102933A (en) |
| CN (1) | CN113164439A (en) |
| AU (1) | AU2019392750A1 (en) |
| BR (1) | BR112021010720A2 (en) |
| CA (1) | CA3121624A1 (en) |
| EA (1) | EA202191543A1 (en) |
| IL (1) | IL283665A (en) |
| SG (1) | SG11202105743RA (en) |
| TW (1) | TW202038936A (en) |
| WO (1) | WO2020118114A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019524747A (en) | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス，インク． | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia |
| CN113368032A (en) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | Pharmaceutical composition, oral solid preparation and preparation method and application thereof |
| TW202330485A (en) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| TW202334103A (en) * | 2021-12-30 | 2023-09-01 | 美商安索治療公司 | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010012656A (en) * | 2008-05-22 | 2010-12-20 | Squibb Bristol Myers Co | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same. |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2014113407A2 (en) * | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| US20160022632A1 (en) * | 2013-03-15 | 2016-01-28 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| JP2019524747A (en) * | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス，インク． | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia |
-
2019
- 2019-12-05 EP EP19891796.5A patent/EP3890722A4/en active Pending
- 2019-12-05 CA CA3121624A patent/CA3121624A1/en active Pending
- 2019-12-05 US US17/311,245 patent/US20220023251A1/en active Pending
- 2019-12-05 CN CN201980080586.8A patent/CN113164439A/en active Pending
- 2019-12-05 WO PCT/US2019/064785 patent/WO2020118114A1/en unknown
- 2019-12-05 EA EA202191543A patent/EA202191543A1/en unknown
- 2019-12-05 SG SG11202105743RA patent/SG11202105743RA/en unknown
- 2019-12-05 AU AU2019392750A patent/AU2019392750A1/en active Pending
- 2019-12-05 KR KR1020217021179A patent/KR20210102933A/en active Search and Examination
- 2019-12-05 JP JP2021531034A patent/JP2022510303A/en active Pending
- 2019-12-05 BR BR112021010720-7A patent/BR112021010720A2/en unknown
- 2019-12-06 TW TW108144816A patent/TW202038936A/en unknown
-
2021
- 2021-06-02 IL IL283665A patent/IL283665A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019392750A1 (en) | 2021-07-15 |
| TW202038936A (en) | 2020-11-01 |
| BR112021010720A2 (en) | 2021-08-31 |
| US20220023251A1 (en) | 2022-01-27 |
| WO2020118114A1 (en) | 2020-06-11 |
| IL283665A (en) | 2021-07-29 |
| JP2022510303A (en) | 2022-01-26 |
| KR20210102933A (en) | 2021-08-20 |
| EP3890722A4 (en) | 2022-08-24 |
| CA3121624A1 (en) | 2020-06-11 |
| CN113164439A (en) | 2021-07-23 |
| EP3890722A1 (en) | 2021-10-13 |
| EA202191543A1 (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3484862T (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| PT3348557T (en) | Compound for treating or preventing hyperuricemia or gout | |
| IL283665A (en) | Methods for treating or preventing gout or hyperuricemia | |
| IL288034A (en) | Compound for treating gout or hyperuricemia | |
| ZA201907975B (en) | Agent for preventing or treating tauopathy | |
| ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL291687A (en) | Methods for treating myelofibrosis and related conditions | |
| GB2589217B (en) | At-the-bit mud loss treatment | |
| IL281792A (en) | Treatment methods | |
| IL281839A (en) | Treatment methods | |
| PL3638630T3 (en) | Method for treating sludge | |
| ZA202001536B (en) | Method for the treatment of wastewaters | |
| GB201804763D0 (en) | Gout treatment | |
| HUE049463T2 (en) | Method for the treatment of ballast | |
| SG11202103619QA (en) | Methods for treating or preventing skin conditions | |
| EP3823648C0 (en) | Methods for treating diabetes | |
| IL284668A (en) | Methods for treating schizophrenia | |
| IL281343A (en) | Methods for treating pancreatitis | |
| IL278984A (en) | Safinamide for treating myotonia | |
| SG10201910408QA (en) | Device for treating dysarthrosis | |
| IL279550A (en) | Compositions and methods for treating trichomonas | |
| GB201803009D0 (en) | Forth alzheimers treatment | |
| GB201706821D0 (en) | Compounds and methods for treating obesity |